Potential COVID-19 Vaccine Yields Promising Results in Trial

Published by Matt Fishman on

In clinical trials, Biotech company Moderna’s vaccine candidate against COVID-19 has effectively produced antibodies¬†to SARS-CoV-2, the virus that causes COVID-19.

45 of the 45 people (or 100%) injected with the vaccine candidate yielded an amount of antibodies exceeding the antibody levels of patients who’ve recovered from COVID-19.

Moderna says the most commonly reported side effects following vaccination were fatigue, chills, headache, and myalgia; “all of which were transient and mild or moderate in severity”.

The next phase of trials will include a much larger sample size, “approximately 30,000 participants”, and should determine whether or not the vaccine is effective at the prevention of COVID-19.